EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNatera, Inc.

About this trial

The purpose of this research is to develop and validate a single gene Non-Invasive Prenatal Test. The development of this investigational single-gene noninvasive prenatal testing (sgNIPT) for conditions such as cystic fibrosis (CF), spinal muscular atrophy (SMA), Sickle cell disease, alpha thalassemia (a-thalassemia) and beta thalassemia (b-thalassemia) could provide information about the possibility that a child will be born with a serious health condition, in some cases in the absence of reproductive partner screening.

In order to develop a test for this purpose, investigators will collect blood samples and medical information from pregnant women who have pregnancies at higher risk for single gene disorders, such as those who are carriers for these conditions or affected by these conditions themselves, medical data from their reproductive partners in some cases, and either genetic testing results or a cheek swab sample from the newborn(s).

Eligibility criteria

Qualifiers

Age 18 or older at the time of informed consent

Maternal participant: Pregnant and blood draw at ≥ 9 weeks gestational age (GA)

Maternal participant is positive for a single-gene disorder and/or there are prenatal ultrasound findings suggestive for a fetal single-gene disorder, including but not limited to the genes listed in the primary and secondary objectives

Both maternal and reproductive partner (paternal) status are positive for the same single-gene disorder OR

Disqualifiers

Reproductive partner found to not be positive for the same autosomal recessive genetic disorder as the pregnant maternal carrier, or vice versa

Surrogate gestation or egg donor pregnancy

Negative preimplantation genetic testing for the single-gene disorder identified in one or both parents

Trial design

Treatments tested in this trial

  • Single-gene Noninvasive Prenatal Testing (sgNIPT)

Treatment groups

4,000 Participants
are divided into 1 treatment group

Sponsors and collaborators